Drug Patents owned by Janssen Therap
1. List of Sirturo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7498343 | JANSSEN THERAP | Mycobacterial inhibitors |
Dec, 2026
(3 years from now) | |
| US8546428 | JANSSEN THERAP | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Mar, 2029
(6 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Aug 9, 2026 |
| New Patient Population (NPP) | Aug 9, 2022 |
Drugs and Companies using BEDAQUILINE FUMARATE ingredient
Market Authorisation Date: 28 December, 2012
Treatment: Treatment of pulmonary multi-drug resistant tuberculosis
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic